SCHEMBL24139765

SCHEMBL24139765

CCc1cnc(OC)c(NS(=O)(=O)c2cccc(C(=O)OC)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 1/20 0.56
▸ ACLY P53396 3/20 0.53
▸ BRD4 O60885 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ PIK3CG P48736 2/20 0.46
▸ PIK3CA P42336 2/20 0.46
▸ PIK3CD O00329 1/20 0.46
▸ EGFR P00533 1/20 0.46
▸ PIK3CB P42338 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TCF4 P15884 2/20 0.46
▸ CTNNB1 P35222 2/20 0.46
▸ MTOR P42345 1/20 0.44
▸ METAP2 P50579 1/20 0.44
▸ CYP2C9 P11712 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16020309 0.93 ALDH1A1 (0.53) SLC40A1ACLYALDH1A1MEN1KMT2A
SCHEMBL24137459 0.90 SLC40A1 (0.45) SLC40A1ACLYALDH1A1MEN1KMT2A
SCHEMBL13976112 0.87 SLC40A1 (0.58) SLC40A1ACLYBRD4ALDH1A1MEN1
SCHEMBL24139843 0.86 SLC40A1 (0.57) SLC40A1ACLYBRD4ALDH1A1MEN1
SCHEMBL24139910 0.84 ALDH1A1 (0.52) SLC40A1ACLYALDH1A1MEN1KMT2A
SCHEMBL13975447 0.84 SLC40A1 (0.55) SLC40A1ACLYBRD4ALDH1A1MEN1
SCHEMBL13975453 0.84 SLC40A1 (0.55) SLC40A1ACLYBRD4ALDH1A1MEN1
SCHEMBL16020322 0.81 KDM4E (0.47) SLC40A1ACLYBRD4ALDH1A1MEN1
SCHEMBL24139833 0.79 SLC40A1 (0.41) SLC40A1ACLYBRD4ALDH1A1MEN1
SCHEMBL16020338 0.79 KMT2A (0.53) ALDH1A1MEN1KMT2AMETAP2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2710018-B1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2021-12-29 — — EP disclosed
Send feedback